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Abstract (max 175 words) 
The current clinical care of glioblastomas leaves behind invasive, radio- and chemo-resistant cells. We 
recently identified mammary-derived growth inhibitor (MDGI/FABP3) as a biomarker for invasive gliomas. 
Here, we demonstrate a novel function for MDGI in the maintenance of lysosomal membrane integrity, thus 
rendering invasive glioma cells unexpectedly vulnerable to lysosomal membrane destabilisation. MDGI 
silencing impaired trafficking of polyunsaturated fatty acids into cells resulting in significant alterations in 
the lipid composition of lysosomal membranes, and subsequent death of the patient-derived glioma cells via 
lysosomal membrane permeabilization (LMP). In a preclinical model, treatment of glioma-bearing mice with 
an anti-histaminergic LMP-inducing drug efficiently eradicated invasive glioma cells and secondary tumours 
within the brain. This unexpected fragility of the aggressive infiltrating cells to LMP provides new 
opportunities for clinical interventions, such as re-positioning of an established anti-histamine drug, to 
eradicate the inoperable, invasive, and chemo-resistant glioma cells from sustaining disease progression and 
recurrence. 
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Introduction 
Gliomas constitute approximately 30 % of all primary nervous system tumours and 80 % of all malignant 
brain tumours (Goodenberger & Jenkins, 2012). Glioblastoma is the most frequent, aggressive, and lethal 
type of gliomas. Glioblastomas harbour a dense abnormal vasculature, display large hypoxic and necrotic 
areas, and contain extensively proliferating tumour cells with the intrinsic ability to disseminate and colonize 
the brain far beyond the primary tumour mass. The current standard of care, comprising surgery, radio- and 
chemotherapy, provides only modest improvement in patient survival, and the prognosis remains dismal 
(Weller et al., 2017). This is due to (i) difficulty of complete surgical resection of the tumour; (ii) 
intratumoural heterogeneity and presence of multidrug-resistant cells and stem cell-like glioma cells 
responsible for the tumour maintenance and relapse, and (iii) the sheltering effect of the blood-brain-barrier 
(BBB), which efficiently prevents administration of many systemic anti-cancer agents into the brain. Most 
probably different approaches are required to eradicate the invasive cells and the cells that reside within the 
tumour bulk (Guishard et al., 2018). Thus, novel therapeutic approaches for glioblastomas are urgently 
needed (Reifenberger et al., 2017). 
 
We have previously identified mammary-derived growth inhibitor (MDGI) as a glioma biomarker expressed 
in tumour cells and their associated vasculature (Hyvonen et al., 2014). MDGI, also known as heart-type 
fatty acid binding protein (H-FABP/FABP3), belongs to the family of fatty acid binding proteins (FABPs) 
that facilitate the intracellular transport of fatty acids (Glatz & van der Vusse, 1996). Both tumour-
suppressive (Nevo et al., 2010) and tumour-promoting (Hashimoto et al., 2004, Sumantran et al., 2015) 
functions, depending on the cancer type, have been reported for MDGI. In glioma cells, MDGI has been 
found to mediate lipid droplet formation and fatty acid uptake (Bensaad et al., 2014) with the highest binding 
affinities to polyunsaturated fatty acids (PUFAs) (Richieri et al., 2000). 
 
Here, we used cohorts of patients operated for primary glioma and patient-derived human spheroid cultures 
to examine the function of MDGI. Primary gliomas abundantly expressed MDGI, and high expression was 
associated with poor patient survival. MDGI was upregulated by hypoxia and its overexpression enhanced 
the invasive growth of glioma cells both in vitro and in vivo. Surprisingly, MDGI silencing compromised 
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spheroid growth and glioma cell survival via lysosomal membrane permeabilization (LMP). Lipid analyses 
of the lysosomal membranes showed that linoleic acid (18:2n-6), the major PUFA in the cell culture 
medium, was inefficiently incorporated into lysosomal phospholipids in MDGI-silenced cells. This led to 
biased molecular species composition of the phospholipids, in conjunction with reduced degree of lysosomal 
ceramide unsaturation. In addition, we show that glioma cells were more sensitive than normal cells to an 
LMP-inducing drug, the anti-histamine clemastine, in vitro, and that clemastine-treatment eradicated the 
invasive glioma cells in vivo. Our results suggest that MDGI expression is crucial for glioma cell viability 
and an important regulator of lysosomal integrity. The vulnerability of invasive glioma cells to lysosomal 
membrane destabilisation opens new opportunities to LMP-inducing drugs as a promising treatment option. 
 
Results 
 
High MDGI expression correlates with poor glioma patient survival 
Our previous results show that MDGI is expressed in a grade-dependent manner in human gliomas and its 
expression positively correlates with the histologic grade (Hyvonen et al., 2014). To study the potential 
correlation of MDGI expression with clinicopathological variables and patient survival, we performed 
immunohistochemistry for MDGI in human tumour microarrays (TMAs) consisting of lower WHO grade 
(grade II-III) gliomas and glioblastomas (grade IV) (Fig 1A), and scored the staining intensity separately in 
tumour cells and tumour-associated endothelial cells. Approximately 50 % of both grade II-III gliomas and 
glioblastomas expressed moderate to high levels of MDGI, accompanied with positive vascular staining for 
MDGI (Supplementary Tables 1 and 2). Only 5 % of all gliomas ( n = 6/122) showed no detectable MDGI 
expression. In the glioblastoma specimens, MDGI expression correlated with the presence of the CD117/C-
Kit-receptor in the perinecrotic tumour regions (P = 0.006) (Supplementary Table 2). MDGI expression did 
not associate with the expression of EGFR (P > 0.999), EGFRvIII (P = 0.613), phosphorylated EGFR (Tyr-
1173) (P > 0.999), or p53 (P = 0.499; Supplementary Table 2).  
 
In lower grade gliomas (grade II-III) moderate to high MDGI levels significantly associated both with poor 
glioma-specific (HR = 1.85; 95 % CI: 1.08-3.16; P = 0.022; Supplementary Fig S1A) and poor overall 
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survival of patients (HR = 1.98; 95 % CI: 1.19-3.28; P = 0.007; Fig 1B) as compared to patients with 
negative or low tumour MDGI expression. Multivariable Cox hazards analysis showed that both MDGI 
expression and high tumour grade independently associated with unfavourable overall survival, increasing 
the risk of death by the factor of 2 (Table 1). In glioblastomas, tumour MDGI levels were not associated with 
overall survival (Supplementary Fig S1B).  
 
Next, we studied MDGI/FABP3 expression in human glioma specimens and its association with survival 
using the GlioVis dataportal (http://gliovis.bioinfo.cnio.es). We analysed MDGI/FABP3 expression in The 
Cancer Genome Atlas (TCGA) RNA seq datasets for glioblastoma (TCGA GBM) and for glioblastoma and 
low-grade glioma (TCGA GBMLGG). In the TCGA GBMLGG dataset, high MDGI mRNA expression 
associated with poor survival (Fig 1C), while no significant association between MDGI expression and 
patient survival was observed in the TCGA GBM dataset (Supplementary Fig S1C). Thus, these results 
corroborate our immunohistochemistry results. When we analysed MDGI expression in the different 
histological glioma subclasses (grades II-IV), significantly more MDGI was expressed in glioblastomas 
compared to the lower grade gliomas (Appendix Fig S1D). When different glioblastoma subtypes were 
analysed, highest MDGI expression was observed in the mesenchymal subtype compared to the classical or 
pro-neural ones (Fig 1D). However, it did not reach the statistical significance. Moreover, the vast majority 
(94 %) of MDGI-expressing glioblastomas displayed the non-G-CIMP phenotype (Appendix Fig S1E). In 
addition, in the lower grade gliomas, no significant difference in MDGI expression was observed between 
the IDH wt and mutant tumours (Appendix Fig S1F). 
 
We then analysed MDGI expression using the Ivy Glioblastoma Atlas project (Ivy_GAP; 
http://glioblastoma.alleninstitute.org) RNA seq dataset, which maps gene expression across the anatomic 
structures and putative cancer stem cell clusters in glioblastomas. Interestingly, MDGI mRNA was expressed 
at significantly higher levels in the leading edge of the tumour and in infiltrative tumour cells compared to 
the microvascular proliferation, pseudopalisading cells, or cells in the tumour mass (Fig 1E). In addition to 
the patient tissue biopsies, MDGI was expressed in all seven distinct patient-derived spheroid cultures 
containing stem cell-like glioma cells, whereas it was very low in 4 of 5 adherent cell lines studied (Fig 1F).  
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Our immunohistochemical results in clinical tumour samples revealed a correlation between MDGI 
expression and perinecrotic C-Kit, which is an indirect hypoxia marker in glioblastomas (Sihto et al., 2007). 
In patient-derived BT12 and BT13 spheroids, MDGI expression was high in conjunction with strong 
expression of hypoxia-inducible factor 1α (HIF-1α) (Fig 1G). Addition of medium supplemented with serum 
led to drastic reduction (70-90 %) in both MDGI and HIF-1α levels (Fig 1G) and shifted the growth from 
spheres to adherent monolayers. Moreover, MDGI expression was highly increased by hypoxia in adherent 
BT5, BT5R, and U87MG cell lines (Figs 1H and EV1A). No increase in MDGI expression in response to 
hypoxia was observed in BT12 and BT13 spheroid cultures, which already express high levels of MDGI and 
HIF-1α under normoxic conditions (Fig 1G and H). These results in glioma cells link MDGI induction to 
hypoxia. 
 
MDGI overexpression promotes glioma cell invasion 
As MDGI expression was associated with glioma cell invasion and poor patient survival, we next studied 
MDGI function in glioma cell growth and invasion. We overexpressed MDGI as a GFP-fusion protein 
(MDGI-GFP) in U87MG cells since they express low endogenous levels of MDGI and form local, non-
invasive tumours following intracranial injection in pre-clinical models (Lee et al., 2006, Xie et al., 2015). 
While MDGI overexpression did not affect cell proliferation (Fig EV1B), it significantly enhanced colony 
formation, suggesting an increased capacity for aggressive, anchorage-independent growth of the MDGI-
overexpressing cells (Fig EV1C and D). In addition, MDGI-overexpressing spheroids grew more invasively 
in an ex vivo brain slice model than the control cells (Fig EV1E and F). Moreover, the intracranial U87MG-
MDGI-GFP xenografts grew invasively (Fig 2A and B), formed secondary tumours (diameter >300 µm) in 
the brain (Fig 2C and D, and G), and displayed vascular co-option (angiotropic tumours with diameter < 300 
µm, Fig 2E and F, and H) unlike the control GFP-expressing U87MG-derived xenografts that only formed 
well-delineated masses. Next, we overexpressed MDGI in the LN229 glioblastoma cells that in addition to 
formation of the primary tumour mass invade into the brain parenchyma and form secondary vasculature-
associated angiotropic tumours. Also, in this model, high MDGI expression significantly promoted the 
invasion and formation of angiotropic tumours (Fig 2I-P) consistent with the results obtained with the 
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U87MG-MDGI-GFP xenograft model. 
 
MDGI silencing reduces glioblastoma cell viability 
To investigate the functions of the endogenous MDGI in glioblastoma cells, we silenced MDGI in patient-
derived BT12 and BT13 cells using two different shRNAs (shMDGI1 and shMDGI2). The shMDGI1 
resulted in undetectable MDGI levels while shMDGI2 showed approximately 60-70 % knockdown 
efficiency (Fig EV2A and B). MDGI silencing caused a dramatic change in the cell morphology abrogating 
the formation of the large multicellular spheroids (Fig 3A). Moreover, the self-renewal ability in 
methylcellulose (Fig 3B and C) and the anchorage-independent growth in soft agar (Fig EV2C) of the 
MDGI-silenced cells was severely compromised. Surprisingly, MDGI silencing inhibited proliferation of 
both BT12 and BT13 cells (Figs 3D and EV2D) and dramatically reduced their viability (Fig EV2E). When 
the MDGI-silenced cells were injected intracranially into immunocompromised mice, no tumour formation 
was observed while the control shRNA (Scr) infected cells formed invasive tumours (Figs 3E and F, and 
Appendix Fig S2A-C). These results demonstrate a dose-dependent effect of MDGI silencing on 
glioblastoma cell growth and viability. 
 
MDGI has been previously shown to affect EGFR trafficking (Nevo et al., 2009), inhibition of which can 
induce glioma cell apoptosis (Ghildiyal et al., 2013, Kaluzova et al., 2015). Thus, we investigated the EGFR 
expression and pathway activity in glioma cells. Only the patient-derived glioblastoma BT11, BT12, and 
BT13 spheroids expressed high levels of EGFR (Appendix Fig S2D). As expected, BT12 and BT13 cells 
were highly sensitive to the commonly used EGFR inhibitor, gefitinib (Wakeling et al., 2002). While 0.4 M 
of gefitinib was able to kill up to 50 % of the BT12 and BT13 cells, 23.5-fold higher concentration (9.4 M) 
was required to kill 50 % of the ZH305 cells that expressed low levels of EGFR (Appendix Fig S2E). EGFR 
expression was significantly reduced in response to MDGI silencing in BT12 and BT13 cells both at the 
mRNA and protein levels (Appendix Fig S2F and G). However, MDGI silencing also induced death of the 
ZH305 spheroids expressing low levels of EGFR, suggesting that MDGI silencing triggered cell death was 
independent of EGFR expression (Fig EV2F and G). 
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MDGI silencing induces caspase-independent death of glioma cells 
To further examine the mechanism underlying the reduced viability of MDGI-silenced cells, we assessed the 
Annexin V binding to the cell surface-exposed phosphatidylserines as a marker of cell death (Koopman et 
al., 1994). MDGI silencing significantly increased the binding of Annexin V to MDGI-silenced BT12 cells 
compared to the control cells, indicating increased apoptosis (Fig 4A and B). To study the intracellular 
pathways that could contribute to this, we analysed the expression of apoptosis-associated proteins at various 
time points after lentiviral MDGI silencing. Levels of the phosphorylated and total p53 and the pro-apoptotic 
protein BAD first remained stable but eventually decreased 5-6 days after transduction (Appendix Fig S3A). 
Surprisingly, the amounts of total caspase-3 and its cleaved, activated form also decreased 5-6 days after 
silencing (Appendix Fig S3A). We also studied the expression of selected proteins of the key signalling 
pathways at different time points after MDGI silencing using Western blot. In MDGI-silenced cells, p27 
levels were elevated and the Erk1/2 phosphorylation was significantly induced, while the phosphorylated 
AKT was decreased already at day three after silencing (Appendix Fig S3B). In addition, in an antibody 
array of apoptosis-associated proteins, levels of the anti-apoptotic proteins survivin and X-linked inhibitor of 
apoptosis protein (XIAP) decreased in MDGI-silenced cells. We also observed a decrease in the active 
caspase-3 level. However, the fold-change (0.61) exceeded the threshold and therefore, it was considered as 
unchanged. On the other hand, levels of the HTRA serine protease were elevated while levels of pro-
apoptotic proteins BAD and BAX or cytochrome C were unchanged by MDGI silencing (fold-change less 
than 0.6 or more than 1.5; Appendix Fig S3C and D). Furthermore, MDGI silencing-induced cell death could 
not be rescued by siRNA silencing of the pro-apoptotic protein BAD (Appendix Fig S3E and F). This 
suggests that apoptosis in the MDGI-silenced cells was not mediated by caspase activation. 
 
MDGI silencing induces lysosomal membrane permeabilization (LMP) 
Since apoptosis in MDGI-silenced cells was not mediated by caspase activation, we studied the effects of 
MDGI silencing on LMP. This alternative cell death pathway leads to release of lysosomal hydrolases into 
the cytosol, and depending on the extent of the release can ultimately lead to lysosomal cell death with 
necrotic or apoptotic features (Aits & Jaattela, 2013). LMP induction can be easily visualised as a change in 
 9 
galectin-1 localization from a diffuse cytoplasmic to a punctate staining pattern (Aits et al., 2015). As a 
control, we first treated the glioma spheroids with an LMP-inducing agent, L-leucine O-methyl (LLOMe) 
(Uchimoto et al., 1999), which caused increased formation of galectin-1 (LGALS1) -positive puncta (Fig 4C 
and D). Similarly, we detected a significant increase in the number of LGALS1-positive punctate staining in 
the MDGI-silenced patient-derived BT12 and BT13 cells (Fig 4E-I). In addition, a significant fraction of the 
MDGI-silenced cells was already dead at the time of analysis, as revealed by the quantification of the 
number of fragmented nuclei devoid LGALS1-staining (Fig 4J). LGALS1-puncta co-localized with the 
lysosomal marker protein, lysosome-associated membrane protein 2 (LAMP2), verifying the lysosomal 
localization of LGALS1 (Fig EV3A). Moreover, the activity of lysosomal cathepsin B was significantly 
increased in the cytoplasm of the MDGI-silenced cells (Fig 4K). Interestingly, when we cultured the BT12 
and BT13 cells with the pan-cathepsin inhibitor (K777), survival of MDGI-silenced cells was partially 
rescued (Fig 4L). Only 11 % of the MDGI-silenced cells were alive at day 5 after shRNA transduction 
compared to the control cells, while 41 % of the MDGI-silenced cells were alive when cultured in the 
presence of K777 compared to the control cells (Fig 4L).  
 
MDGI silencing changed lysosomal membrane lipid composition 
To investigate whether MDGI silencing would affect the lysosomal membrane lipid composition due to its 
fatty acid binding and transport function, we enriched lysosomes by density gradient ultracentrifugation (Fig 
EV4B) and analysed the extracted lysosomal lipids by mass spectrometry. The lipid classes with most 
evident compositional differences between the MDGI-silenced and control cells were phosphatidylcholine 
(PC), phosphatidylethanolamine (PE), and ceramide. PC and PE are the bulk lipids of the membrane that 
together comprise about 70 % of the lysosomal membrane phospholipids (Kobayashi et al., 2002). 
Lysosomes of the MDGI-silenced cells contained decreased proportions of di-unsaturated PC and PE species 
compared to the lysosomes of the control cells (Fig 5A), especially the 36:2 was diminished due to the 
silencing (Fig 5B). At the same time, the proportions of monounsaturated PC and PE species (34:1 and 36:1) 
increased and those of saturated PC species (30:0 and 32:0) decreased compared to the lysosomes of the 
control cells (Fig 5B). While no differences were observed in the total proportions of the more highly 
unsaturated PC and PE species (double bond content 3–7) in response to MDGI silencing (Fig 5A), certain 
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polyunsaturated species with 3 or 4 double bonds were increased (PE 38:3, 40:3, 36:4, 38:4) in conjunction 
with decrease in species with 5-7 double bonds (PE 40:5, 40:7) (Fig 5B). 
 
Ceramides (Cer), regarded as important determinants of membrane permeability, have only one N-linked 
acyl chain, which commonly is either saturated or monounsaturated. Lysosomes of the MDGI-silenced cells 
showed a marked compositional change of ceramide species (Fig 5C). In the control cell lysosomes Cer 24:1 
dominated by three-fold over Cer 24:0, while in the lysosomes of the MDGI-silenced cells these two Cer 
species were found in equal amounts (Fig 5C and D). The consequent impairment of the elastic properties of 
membrane bilayer (Bruno et al., 2007, Pan et al., 2009) probably contributed to the found leakage of 
lysosomal membranes. 
 
Clemastine evokes glioma cell death  
Inspired by MDGI silencing-triggered cell death via LMP, we searched for an LMP-inducing drug that could 
be safely used in pre-clinical studies. A recent report by Ellegaard et al. identified cationic amphiphilic 
(CAD) anti-histamines as drugs able to provoke LMP (Ellegaard et al., 2016). Therefore, we chose 
clemastine (Tavegil™), a first-generation histamine H1 blocking antihistamine CAD, as the BBB-permeable 
drug for our experiments. The patient-derived BT12, BT13, and ZH305 glioblastoma cells, as well as various 
normal cells, were treated with increasing concentrations of clemastine (1-5 M). The highest concentration 
killed all the cells in vitro already by day 3 (Fig 6A and B). About 90 % cell death was observed with 2 M 
clemastine concentration, while 1 M clemastine concentration killed 50 % of BT12 and BT13 cells and 64 
% of ZH305 cells at day 4 (Fig 6A). No significant cell death was observed when normal human endothelial 
cells (HuAR2T), normal human astrocytes (NHA), embryonic kidney (HEK293T) (Fig 6B) or murine brain 
endothelial (Fig EV3C) cells were treated at 1-2 M of clemastine, suggesting a therapeutic window for 
clemastine-treatment in gliomas. In accordance, already 1 M of clemastine induced punctate localization of 
the galectin-1 in BT12, BT13, and ZH305 cells (Fig 6C) whereas no galectin-1 re-localization was observed 
in HuAR2T, NHA or HEK293T cells (Fig 6D). Galectin-1 relocation into the lysosomes cells was confirmed 
by co-localization with the LAMP2 (Fig EV3D). Clemastine-treatment had no effect on MDGI levels in 
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glioblastoma cells in vitro (Appendix Fig S4A), suggesting that the clemastine effect is not upstream of 
MDGI. 
 
The preclinical evaluation of clemastine was performed in patient-derived xenografts orthotopically 
implanted in immuno-compromised mice. We chose three different patient-derived glioblastoma models 
with different intracranial growth patterns: BT13 cells grow as an angiogenic non-invasive tumour, ZH305 
cells grow highly diffusively without formation of tumour bulk, and BT12 cells show a mixed phenotype 
with tumour bulk and invasive growth. After 15 days of tumour growth, we started intraperitoneal injections 
of clemastine at a dose of 100 mg/kg on the first day followed by 50 mg/kg daily injections for 12 additional 
days. The vehicle (saline solution) was administered under the same modalities to the control cohort. As 
illustrated in Fig 7A, clemastine provoked a profound alteration in the growth pattern of BT12, BT12 Scr, 
and ZH305 derived xenografts. No difference was observed in the BT13-derived xenografts that form bulky 
angiogenic tumours without invasive tumour cells (Fig 7A). The MDGI-silenced BT12 cells did not form 
tumours in vivo (Figs 3E and EV4A and B). The number and distance of invasive cells that had escaped the 
primary tumour and disseminated into the brain were dramatically reduced (Fig 7B and C) to the extent that 
in the ZH305 model no tumour cells were detected (Figs 7A and EV4C). In addition, clemastine-treatment 
significantly reduced the number of secondary tumours in BT12 and BT12 Scr xenografts (Fig 7D). In 
addition, clemastine-treatment led to a nearly complete loss of co-opting angiotropic tumour cells (Fig 7E). 
To further evaluate the anti-tumour effect of clemastine, we analysed the number of apoptotic cells by 
terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) in control and clemastine-treated 
BT12-xenograft bearing animals. Whole brain quantification revealed that the leading, migratory edge of the 
tumour was more susceptible to the cytotoxic effect of clemastine (Fig 7F and G) than the cells inside the 
tumour mass. As a consequence, clemastine-treated animals showed significantly prolonged survival (P = 
0.044) compared to the controls (Fig 7H). To study whether clemastine affected galectin-1 localization as a 
sign of LMP induction also in vivo, we analysed the BT12-derived control and clemastine-treated xenografts 
by using immunohistological and Western blot analyses. Clemastine induced re-localisation of galectin-1 
into a more punctate pattern (Fig EV4D and E) but did not affect the galectin-1 expression levels (Fig 
EV4F). No cytotoxic effect of clemastine apart from the transient drowsiness of the animals following drug 
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injections was observed during the treatment. We weighted the animals during the treatment and post-
mortem measured selected organs’ weight. The vehicle-treated animal lost weight at the end of the treatment 
probably due to the tumour burden (Appendix Fig S4B) but no significant difference in the organ:body 
weight ratios were observed between the vehicle and clemastine -treated animals (Appendix Fig S4C-F). 
 
Discussion 
 
There is an unmet need for novel therapeutic strategies to treat gliomas, making the characterization of 
proteins involved in disease progression highly imperative. Here we examined the expression of a potential 
glioma biomarker, MDGI (Hyvonen et al., 2014), in WHO grade II-III glioma and glioblastoma (grade IV) 
specimens, publicly available datasets as well as in patient-derived and commercially available glioblastoma 
cell lines. We show that high MDGI expression associated with unfavourable patient survival and was 
crucial for glioblastoma cell viability. We further describe a novel function for MDGI in the maintenance of 
lysosomal membrane integrity and show the exceptional vulnerability of invasive glioma cells to 
destabilisation of lysosomes. In addition, we show that antihistaminergic drug clemastine eradicated invasive 
glioblastoma cells in vivo via induction of lysosomal membrane permeabilization and prolonged survival of 
glioblastoma-bearing mice. 
 
Although MDGI expression has been linked to tumour suppressive properties in breast cancer (Nevo et al., 
2010), in gastric carcinomas MDGI associated with poor patient survival (Hashimoto et al., 2004) and in 
melanomas its expression was upregulated during disease progression (Sumantran et al., 2015). Here we 
show that MDGI was frequently expressed in human gliomas, and high MDGI expression significantly 
correlated with poor survival. These results suggest that the effect of MDGI on tumorigenesis may be tissue 
and cancer type-dependent. We detected high MDGI expression also in various patient-derived, cancer stem 
cell-enriched spheroids but not in adherent cells under normoxia. However, hypoxia stimulated MDGI 
expression in adherent cells. This is in agreement with previous data that showed upregulation of MDGI 
expression during hypoxia (Bensaad et al., 2014). MDGI overexpression in glioma cells significantly 
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promoted their anchorage-independent growth and invasion both in vitro and in vivo, suggesting a functional 
role for MDGI in the invasive growth. Consistent with this, MDGI/FABP3 expression was highest in the 
mesenchymal subtype of glioblastomas (GlioVis) as well as in the leading edge and infiltrating tumour cells 
based on tumour structure-specific mRNA expression dataset of glioblastomas (IVY_GAP).  
 
Interestingly, our results demonstrate that MDGI expression is crucial for glioma cell survival, and MDGI 
depletion induces lysosomal membrane permeabilization (LMP). LMP is an intracellular cell death pathway 
that can be either caspase-independent or caspase-dependent and it can occur either up- or downstream of 
mitochondrial membrane permeabilization depending on the cell type and/or LMP-inducer (Aits & Jaattela, 
2013, Boya et al., 2003, Huai et al., 2013, Shen et al., 2013). As a consequence LMP results in irreversible 
leakage of lysosomal proteolytic enzymes to the cytoplasm, where they digest vital proteins and intracellular 
organelles (Kirkegaard & Jaattela, 2009). Considering the function of MDGI as a fatty acid binding protein, 
we hypothesised that LMP may be induced by changes in lysosomal membrane lipid composition. Indeed, 
MDGI has been reported to bind efficiently the polyunsaturated fatty acids (PUFAs) (Richieri et al., 2000), 
and in the MDGI knockout mice, incorporation of PUFAs into phospholipid membranes was reduced 
(Murphy et al., 2005). Our lipid analyses show that MDGI silencing impaired trafficking of polyunsaturated 
fatty acids (FA) into cells resulting in significant alterations in the lipid composition of lysosomal 
membranes. Among the FAs preferred by MDGI is linoleic acid 18:2n-6, which cannot be synthesised de 
novo by the cells but has to be received from external sources. In fact, 18:2n-6 was the main FA component 
in cell culture media used in this study suggesting that MDGI silencing impaired the uptake and 
incorporation of the 18:2 FA chain into the lysosomal phospholipids. Mammalian cells actively regulate their 
membrane fluidity, and when the supply of exogenous PUFAs diminishes, the endogenous production of 
monounsaturated FAs (MUFAs) from the saturated FA (SFA) precursors by desaturases is activated 
(Ntambi, 1999). In line with this, the lysosomal membranes of MDGI-silenced cells contained larger 
proportions of MUFAs and fewer SFAs than the control lysosomes, which can be seen as fluidity 
compensation among these membrane bulk phospholipids. However, it should be recalled that MUFAs 
cannot replace the essential PUFAs in their specific biological functions, and it is likely that this 
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compositional bias caused by MDGI silencing hampered lysosomal membrane integrity, dynamics, and 
vesicle secretion, and changed the precursor pool of signalling molecules (Erazo-Oliveras et al., 2018). 
 
Membrane ceramide content has been considered as an important factor defining membrane permeability, 
albeit the mechanistic explanations vary from pore induction to gradually increasing defects in lipid packing 
(Artetxe et al., 2017). The lysosomes of the MDGI-silenced cells showed no marked change in the total 
ceramide content or their acyl chain length distribution, commonly attributed to cell fate decisions and 
induction of apoptosis (Grosch et al., 2012). Our data, however, identified ceramides as potential mediators 
of LMP, since the degree of unsaturation of the lysosomal ceramides (ratio of Cer 24:1 to Cer 24:0) 
markedly decreased upon MDGI silencing. These observed changes in the ceramide FA saturation are 
plausibly large enough to affect lateral packing and dynamics of the lysosomal membrane. Loss of the 
unsaturated Cer 24:1 species from the lysosomal membrane, leaves behind a membrane enriched with more 
rigid saturated 24:0, which probably made the membrane less elastic and prone to leakage. 
 
In addition to the impaired membrane integrity and elasticity, activation of Erk in the MDGI-silenced cells 
could play a role in the process, since phosphorylated Erk (besides being linked to apoptosis-induction and 
cell cycle arrest (Woessmann et al., 2002)) has also been shown to enhance cysteine cathepsin expression 
and activity, sensitizing cells to LMP (Fehrenbacher et al., 2008). In addition to the LMP, we also observed 
decreased activity of the AKT kinase (the master regulator of various cell survival pathways (Chang et al., 
2003), downregulation of anti-apoptotic proteins XIAP and survivin, which has been linked to caspase-
independent apoptosis (Kang et al., 2008) as well as an upregulation of the pro-apoptotic serine protease 
HTRA (Eckelman et al., 2006). HTRA contributes to cell death by downregulating XIAP protein levels 
(Vande Walle et al., 2008) and decreases the chemo-resistance of colon cancer cells (Xiong et al., 2017).  
 
A very recent study by Guishard et al. showed an evident translational gap in the past clinical trials of 
glioma: attempts to include drugs that are able to overcome the chemoresistance of glioma stem cells and 
cross the BBB were not made. However, in the ongoing trials, this has been taken better into account but 
there is still room for improvement (Guishard et al., 2018). LMP induction has been shown re-sensitize 
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multidrug resistant cells to chemotherapy and shown efficacy against apoptosis-resistant cancer cells 
(Ellegaard et al., 2013, Groth-Pedersen & Jaattela, 2013). LMP induction in glioblastoma treatment has not 
been widely studied, but several studies have recently characterized the mechanism of action of some novel 
chemotherapeutics and shown that lysosomal dysfunction is a major contributor in drug-mediated cancer cell 
death (Gonzalez et al., 2012, Gutierrez et al., 2016, Jiang et al., 2016). Among the drugs currently on the 
market, cationic amphiphilic (CAD) antihistamines induce lysosomal cell death. Moreover, the use of the 
CAD antihistamines was associated with significantly reduced all-cause mortality among cancer patients 
when compared with the use of non-CAD antihistamines and adjusted for potential confounders (Ellegaard et 
al., 2016). We chose an older generation CAD antihistamine, clemastine, due to its ability to cross the BBB, 
to test the sensitivity of our patient-derived glioblastoma cells towards drug-induced LMP. Clemastine is 
devoid of neurotoxic effects (Liu et al., 2016) even though it causes reported fatigue-induced side effects 
common to many of the antihistaminergic drugs (Verster & Volkerts, 2004). Moreover, clemastine is FDA-
approved and currently under clinical evaluation for multiple sclerosis (Green et al., 2017). We observed a 
dramatic loss of the glioblastoma cell viability that was associated with the loss of lysosomal membrane 
integrity at doses that did not affect the proliferation or viability of several normal cells in vitro. When we 
evaluated the pre-clinical efficacy of clemastine, the survival of animals bearing intracranial glioblastoma 
xenografts was significantly prolonged compared to controls due to the eradication of the invasive glioma 
cells. Both the co-opted, angiotropic growth and single cell invasion, as well as collective migration of 
glioblastoma cells, were inhibited by the systemic delivery of clemastine leading to a nearly complete loss of 
disseminated cells. The observed cytotoxic effect of clemastine targeted preferentially glioblastoma cells in 
the vicinity of functional blood vessels and at the leading edge of the primary tumour mass leading to 
eradication of the secondary tumours. It is known that intratumoural vasculature in glioblastoma is highly 
aberrant and non-functional (McDonald & Choyke, 2003). Similarly to challenges in delivering systemically 
administered chemotherapeutics (Bianco et al., 2017), clemastine delivery into the primary tumour mass may 
partially have been compromised due to poorly functional tumour blood vessel network. Lack of clemastine 
efficacy in reduction of the primary tumour volume may also be due to the dense connective network within 
the tumour bulk that has been shown to provide exceptional protection of glioblastoma cells to radiotherapy 
(Osswald et al., 2015). 
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Many triggers of the LMP are known (Aits & Jaattela, 2013, Appelqvist et al., 2013, Cesen et al., 2012), but 
genes and cellular pathways that regulate the lysosomal membrane integrity remain poorly understood. Our 
study demonstrates the crucial role of MDGI in glioma cell survival, linking this fatty acid binding protein to 
the maintenance of lysosomal membrane integrity. The inoperable, highly invasive and chemo-resistant 
glioma stem cell-like cells showed an unexpected fragility towards LMP. Thus, our study provides a 
potential answer to the clinical challenge for the management of the cells that eventually will lead to the 
recurrence of the disease. These results also suggest re-positioning of an old drug with a new indication. 
More widely, LMP-inducing agents should be considered as a possible novel treatment option for gliomas. 
 
Materials and methods 
 
Glioma patient cohort 
The glioblastoma and grade II-III glioma patient biopsies were obtained from the Department of Pathology, 
Helsinki University Hospital, Finland. The cohort has been described elsewhere (Joensuu et al., 2005, 
Puputti et al., 2006). Briefly, glioblastoma TMA was composed of formalin-fixed paraffin embedded (FFPE) 
tumours derived from 43 craniotomy patients, subsequently diagnosed with primary glioblastoma between 
October 2000 and December 2003. The median survival time of the patients was nine months (range 1-40 
months) as calculated from the date of the diagnosis to the date of death. All patients died due to 
glioblastoma during follow-up. In seven cases, tissue microarray sample was missing or staining was not 
informative leaving 36 patients in the series. 
 
FFPE grade II-III glioma TMAs were prepared from the tumours of 122 patients who were operated for a 
primary glioma at the Helsinki University Hospital between 1979 to 2000. In ten cases, tissue 
microarray sample was missing or staining was not informative leaving 112 patients for the analysis. 33 of 
the tumours (30 %) were diagnosed as astrocytoma, 16 (14 %) as anaplastic astrocytoma, 36 (32 %) as 
glioblastoma, 18 (16 %) as oligodendroglioma and 9 (8 %) as oligoastrocytoma. The association of MDGI 
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with clinical and histopathological factors was studied from 76 low-grade samples, excluding glioblastoma 
patients and the median follow-up time after surgery was 6.0 years (range 0.6-17.0 years). Ten of the patients 
lived at the end of the follow-up, while 58 and 8 patients died from glioma or other causes, respectively.  
 
 
Immunohistochemistry and evaluation of immunostaining 
The immunohistochemical stainings using antibodies against SCF/Kit, CD117/KIT-receptor, CD133, EGFR, 
EGFRvIII, p53 and phosphorylated EGFR (Tyr1173) have been described elsewhere (Joensuu et al., 2005, 
Puputti et al., 2006). For immunohistochemical analyses, MDGI expression was detected from the FFPE-
samples using TSA kit (Perkin Elmer) according to manufacturer´s instructions. The antigen was retrieved 
with heat treatment in citrate buffer (1.8mM citric acid, 8.2mM sodium citrate, pH 6.0). The sections were 
blocked for 10 min with (10 min with 3% H2O2 in methanol, 30 min with TNB-buffer (0.1M Tris-HCl, pH 
7.5, 0.15M NaCl, 0.5% blocking reagent from the TSA kit), incubated with primary antibody overnight at 
4°C and with biotinylated secondary antibody (goat anti-rat immunoglobulin, Dako). The staining was 
amplified by using SA-HRP and biotinylated tyramide and finally visualized with AEC (0.95M 3-amino-9-
ethylcarbazole, 6% N,N dimethylformamide, 94% Sodium Acetate, 0.01%  H2O2). The sections were 
counterstained with Mayer's haematoxylin. 
 
MDGI expression was evaluated blinded to the clinical data and scored as follows: 0, all tumour cells 
negative; 1, low expression in tumour cells (5 % to 50 %); 2, moderate expression in ≥ 50 % of tumour cells; 
and 3, high expression in ≥50 % of tumour cells. For the statistical analyses, tumours with MDGI expression 
scored as 0 and 1, were grouped together as well as tumours with MDGI expression scored as 2 and 3. 
Vascular expression of MDGI was scored as follows: 0, no MDGI-positive vessels; 1, one or more MDGI-
positive vessels. 
 
Patient-derived cells 
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The glioma patient samples were obtained from surgeries (Kuopio University Hospital, Finland) during years 
2010-2011. BT5 cells were obtained from a human gliosarcoma and BT5R cells from its relapse. BT11 cells 
are from a glioblastoma-containing oligocomponents, BT12 and BT13 cells are from glioblastoma patients. 
Informed consent was obtained from all subjects and that the experiments conformed to the principles set out 
in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. 
 
Tumours were collected into solution (0.1% BSA (Biowest), 1M glucose in PBS) centrifuged for 1 min at 
250 x g and suspended into trypsin-hyaluronidase-kynurenic acid-mixture (1.33% trypsin, 0.7% 
hyaluronidase, 0.2% kynurenic acid, 10 000 U/ml DNase in 1 x HBSS-solution containing 1M glucose and 
1M HEPES). Samples were incubated at +37 °C for 15-30 min and triturated with a pipette to break down 
tissues clumps. After filtering through 100 μm nylon mesh filter the cells were centrifuged for 5 min at 250 x 
g. Cell pellets were suspended into sucrose solution (30.8 % glucose in 0.5 x HBSS) and centrifuged again 
for 10 min at 500 x g. Cells were suspended in 2 ml of 1 x EBSS-medium and pipetted on top of 15 ml of 
BSA-EBSS-HEPES-solution (4% BSA, 1M HEPES in 1 x EBSS). After centrifugation for 7 min at 350 x g, 
the cells were suspended into the complete growth medium. Trypsin, hyaluronidase, kynurenic acid and 
DNase were obtained from Sigma. HBSS and EBSS were obtained from Gibco and 1M HEPES-buffer from 
Lonza. 
 
Cell culture 
The patient-derived brain tumour cells (BT3, BT11, BT12, BT13, BT5, BT5R) were maintained for up to 20 
passages in Dulbecco's Modified Eagle Medium with Nutrient Mixture F-12 (DMEM/F12, Gibco) 
supplemented with 2 mM L-glutamine, 2 % B27-supplement (Gibco), 100 U/ml penicillin and 100 µg/ml 
streptomycin, 0.01 g/ml recombinant human fibroblast growth factor-basic (FGF-b, Peprotech), 0.02 μg/ml 
recombinant human epidermal growth factor (EGF, Peprotech) and 15 mM HEPES-buffer. The ZH161, 
ZH305, and S24 were maintained for up to 10 passages in phenol red-free Neurobasal medium (Gibco) 
supplemented with the same ingredients as described above except 0.02 μg/ml of FGF-b was used. We 
confirmed by gas chromatography that the medium provided the cells with linoleic acid (18:2n-6) as the 
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main PUFA (50.3 mol % per total FAs). All the cells were maintained and grown at 37oC in a humidified 
atmosphere containing 5 % CO2 unless stated otherwise. Mycoplasma contamination was routinely checked 
twice a month using the mycoplasma detection kit (11-1050, Minerva Labs).  
 
Commercial cell lines 
The human embryonic kidney cells (293FT, ATCC) were maintained from passages 10 to 25 in DMEM 
containing 4.5 g/l glucose, 10% FBS, 1% L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. 
Human glioma cell line U87MG and murine brain microvessel endothelial cells bEND3 (ATCC) were 
maintained for not more than 10 and 15 passages, respectively, in DMEM containing 1g/l glucose, and with 
the same supplements described above. The generation of stable human U87MG cell lines overexpressing 
green fluorescent protein (GFP) or MDGI as GFP-fusion (MDGI-GFP) has been previously described (5). 
The immortalized human umbilical vein endothelial cells (HuAR2T) were obtained from the Ojala Lab 
(University of Helsinki, Finland) and maintained from passages 15 to 25 in Endothelial Basal Medium 2 (C-
22211) added with Supplements Pack Endothelial Cell GM2 (C-39211) (Promocell) and 2 µg/ml 
doxycycline. 
 
Lentivirus production and generation of MDGI-silenced cells  
The MDGI/FABP3 shRNA-constructs in the pLKO.1 vector were obtained from the RNAi Consortium 
shRNA library (Broad Institute of MIT and Harvard). The sequences were as follows: shMDGI1: 
5’GACCAAGCCTACCACAATCAT3’, shMDGI2: 5’GACAGGAAGGTCAAGTCCATT3’.  
 
Second-generation lentiviruses were produced by co-transfecting the MDGI shRNA or Scr-containing 
plasmids and lentiviral packaging plasmids CMVg and CMV8.9 (Addgene) together with Fugene6-
transfection reagent (Promega) into 293FT cells. After 72 h the virus-containing supernatants were collected 
and filtrated. On the day of transduction, human glioma cell spheres were dissociated with Accutase (Gibco) 
and transduced with viral supernatants together with 8 g/ml Hexadimethrine bromide (Sigma). On the next 
day, the cells were supplied with the fresh complete medium. MDGI silencing was verified using Western 
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blot and real-time qRT-PCR. 
 
Immunofluorescence 
In order to attach the suspension cells, glass coverslips were first coated with Poly-D-Lysin (Sigma) 
according to manufacturer´s instructions. Cells were cultured for 24h after which they were fixed with 4% 
PFA and permeabilized with 0.5% NP40 in PBS. The cells were blocked with 3% BSA-PBS and incubated 
with the primary and fluorescently labelled secondary antibodies (Alexa Fluor, Life technologies). Nuclei 
were visualized with DAPI (Vectashield, Vector Laboratories). 
 
Western blot 
The cells were lysed either in RIPA-buffer (150 mM sodium chloride, 50 mM Tris, 2 mM EDTA, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulphate SDS, 0.5 mM DTT, Complete ultratablet protease 
inhibitor, (Roche)) or in SDS-buffer (150 mM Tris, pH 6.8, 1.2% SDS, 30 % glycerol, 15 % β-
Mercaptoethanol). Protein concentrations of the extracts were determined spectrophotometrically (Pierce 
BCA Protein Assay Kit, Thermo Scientific). 10-20 µg of protein was loaded to a 12% SDS-PAGE gel 
followed by a transfer to PVDF membrane (Immobilon, Millipore) either by electroblotting in transfer buffer 
(20% MetOH, 250 mM Tris, 1.9 M glycine) 100V for 1h at +4°C or by Transblot Turbo device (Biorad) 
using manufacturer´s instructions. After blocking (5% BSA in 0.1 % TBS-Tween) the membrane was probed 
with the primary antibodies o/n at +4oC. After several washes, the membrane was probed with horseradish 
peroxidase-conjugated secondary antibodies, washed again and finally visualized using the SuperSignal 
West Pico kit (Thermo Scientific) or with Clarity Western ECL (Bio-Rad). 
 
Quantitative real-time PCR 
RNA extraction was performed using the Nucleospin RNA II kit (Macherey-Nagel) and reverse-transcribed 
into complementary DNA (cDNA) with High-capacity cDNA Reverse Transcription Kit and MultiScribe 
Reverse Transcriptase (Applied Biosystems). Quantitative real-time PCR (qRT-PCR) was performed using 
SYBR Green PCR Mix (Kapa Biosystems). Relative gene expression was normalized to ADP-ribosylation 
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factor 1 (ARF1) housekeeping gene. Relative quantification of the expression levels between the samples 
was performed according to the Delta Ct method (Ct). Primer sequences in 5´-3´-direction were as follows: 
MDGI (fwd): CCTGGAAGCTAGTGGACAGC; MDGI (rev): TAGCAAAACCCACACCGAGT; EGFR 
(fwd): TCCAGTGGCGGGACATAGT; EGFR (rev): TGGATCACACTTTTGGCAGC; ARF1 (fwd): 
TCCCACACAGTGAAGCTGATG; ARF1 (rev): GACCACGATCCTCTACAAGC. 
 
MTT- proliferation assay 
5000 cells/well were plated on 96-well plates in 3-10 replicates (100 l volume). At the indicated time 
points, 10 l of 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) (5 mg/ml in PBS) 
was added and the cells were incubated for 2 hours. Finally, the cells were lysed (10% SDS, 10 mM HCl) 
o/n and the absorbance was measured at 540 nm using Multiskan Ascent software version 2.6 (Thermo 
Labsystems). 
 
Cell viability and apoptosis 
Trypan blue exclusion method was used to estimate the cytotoxic effects of MDGI silencing. Cells were 
diluted 1:2 in 0.4% Trypan blue solution (Sigma), after which viable and dead cells were counted. The 
percentage of viable cells was determined as follows: (number of viable cells/total cell number) x 100. The 
proportions of apoptotic cells were determined with Annexin V staining which binds to phosphatidylserine 
residues translocated to the outer cell membrane during early stages of apoptosis. Cells were dissociated with 
Accutase and stained with Annexin V conjugate (Annexin V Alexa Fluor 488, Molecular Probes), for 15 min 
in RT. After washes with binding buffer (10 mM HEPES – 140 mM sodium chloride – 2.5 mM CaCl2), the 
lentiviral transduced cells were fixed with 4 % PFA (containing 2.5 mM CaCl2) for 10 min at +4°C, 
suspended into binding buffer and analysed with flow cytometer (BD Accuri C6) equipped with appropriate 
lasers. Cell gating and data analysis was performed using FlowJo v10.1 software (Tree Star Inc.). 
 
Apoptosis arrays 
Expression of apoptosis-associated proteins was determined using the Human apoptosis antibody array 
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(ab134001, Abcam) containing antibodies against 43 proteins in duplicates and additional reference spots. 
Membranes were incubated with 335 µg of cell extracts, immunoblotted and exposed to X-ray films (Super 
RX, Fuji Medical) according to manufacturers’ instructions. Pixel densities of each protein spot were 
determined by using the ImageJ software. 
 
EGFR inhibition  
Glioma cells (5x103) were plated on 96-well plates in triplicates and treated with various concentrations (0.1-
10 μM) of gefitinib (InvivoGen, USA).  After 48h MTT was added, cells were lysed and the absorbance was 
measured as described above. Half-maximal inhibitory concentration (IC50) was determined for each cell line 
using the following formula: IC50 = (50%-Low Inh%)/(High Inh%-Low Inh%)x(High Conc-Low Conc) + 
Low Conc, where: Low Inh%/High Inh% = % inhibition directly below/above 50% inhibition; Low 
Conc/High Conc = Corresponding concentrations of the test compound. 
 
Colony forming cell assay in methylcellulose 
Methylcellulose stock solution (3 %) and protocol were obtained from the R&D Systems. Briefly, 1 x 104 
cells were suspended as single cells in complete medium containing the growth factors EGF and FGF-b and 
semi-solid matrix Methylcellulose stock solution (final concentration 1.3 %). One millilitre of the final cell 
mixture was added into 35-mm plate in triplicates and incubated for three weeks at 37°C containing 5 % 
CO2. The colonies were imaged using Nikon Eclipse Ti-E inverted microscope and quantified using the 
CellProfiler cell image analysis software (http://cellprofiler.org/citations/). The experiment was repeated 
three times. 
 
Anchorage-independent growth assay 
Cells (3000/35-mm well, triplicates) were suspended in medium containing 0.35% agarose and pipetted into 
6-well plates containing a 2-ml layer of solidified 0.7% agar in the medium. Complete medium was added 
twice a week. After 14 (U87MG) or 27 (BT12 and BT13) days, eight images per well were taken (Zeiss 
Axiovert) and the number of colonies was quantified using the ImageJ software (National Institute of Health, 
USA). The experiment was repeated twice. 
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Hypoxia and serum starvation 
For the hypoxia treatment 3x105 cells were plated on 35 mm dishes one day before the experiments. The 
cells were incubated at 37oC in a hypoxia chamber (Ruskinn Technology limited, UK) in 1% of O2 and 5% 
of CO2 for 24 h. For the FBS-treatments, 3x105 cells were plated on 35 mm dishes and grown for 7 days in 
DMEM containing 10% FBS or in serum-free DMEM/F12. Afterwards the cells were washed with ice-cold 
PBS, lysed and analysed with Western blot. 
 
Ex vivo brain slice cultures 
Female FVB mice (5-8 weeks of age) were anesthetized and their brains were removed. Cerebellum was 
excised and the two hemispheres were embedded into 4% Low Melting Point Agarose (Thermo Scientific) in 
PBS. Slices of 500 μm were cut with a vibratome (HistoLab) and placed on top of 0.4 μm filter membranes 
(Millipore) in 6-well plates. Neurobasal A (1 ml, Gibco) supplemented with 1 mM glutamine, 2% B-27 
(Gibco) and 1% penicillin/streptomycin was added to the bottom of each well.  The medium was changed 
every other day. The slices were incubated for one week (37°C, 5% CO2) before starting the experiments 
(Ohnishi et al., 1998). The spheres were formed o/n in U-shaped 96-well plates coated with 0.6% agarose 
(4000 cells/well), after which they were placed to the brain slices. The GFP-fluorescent spheres were imaged 
at indicated time points by taking 10 μm optical slices with Leica TCS SP2 confocal microscope. Image 
stacks were generated using the ImageJ-software and the number of invaded and migrated cells/cell groups 
were quantified manually. The experiment was repeated twice with 3-5 individual spheres/cell line/slice in 
each experiment.  
 
Analysis of lysosomal membrane permeabilization 
LMP was determined using the LGALS1 puncta-staining assay (Aits et al., 2015). BT12 cells treated with 2 
mM L-leucine O-methyl ester (LLOMe, Santa Cruz Biotechnology) were used as positive controls for LMP. 
For the quantification of LGALS1 staining (cytoplasmic/puncta), DAPI and LGALS1-stained cells grown on 
PDL-coated coverslips were scanned with 3DHISTECH Pannoramic P250 FLASH II using Zeiss Plan-
Apochromat objective (20x/NA 0.8) and pico.Edge 4.2 CMOS camera. The number of LGALS1-stained 
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cells (cytoplasmic/puncta) and unstained dead cells were manually calculated from each coverslip ( n = 6, 50 
mm2 area) using Panoramic viewer-software (3DHISTECH.) 
 
Cytoplasmic Cathepsin B activity measurement 
Protocol was modified from Jäättelä and Nylandsted (Jaattela & Nylandsted, 2015). Cells (2x104) in 100 μl 
of complete medium and growth factors were plated in poly-D-lysine coated 96-well plates in quadruplicates 
and incubated O/N. Cytosolic and total cell extracts were prepared by incubating the cells in digitonin 
extraction buffer on ice for 15 min on a rocking table. Used digitonin concentrations for cytosolic and total 
cell extractions were 20 μg/ml and 200 μg/ml, respectively. After transferring the extracts into a new 96-well 
plate, the cells were lysed in SDS-lysis buffer and protein concentrations were determined using the Pierce 
BCA Protein Assay Kit (Thermo Scientific) according to the manufacturer's instructions. To measure the 
cathepsin B activity, 50 μl of cytosolic and total extracts were mixed with 50 μl of reaction buffer containing 
cathepsin B substrate (Calbiochem) in a black 96-well plate. The plate was preincubated at 30°C for 5 min 
and then the kinetics of cathepsin B activity was measured using FLUOstar Omega Microplate Reader 
(BMG Labtech) at 30°C for 20 min (Ex 380 nm; Em 460 nm; 45 sec interval). To calculate the cytosolic 
cathepsin B release, measured enzyme activities were first normalized to the corresponding protein 
concentration of the same well and then cytoplasmic activity was compared to the total cellular activity. The 
experiments were started at day 3 post-lentiviral transduction and repeated three times. 
 
Pan-cathepsin inhibition assay 
For cathepsin inhibition assays, 5x103 cells in 100 μl of complete medium and growth factors were plated in 
96-well plates in triplicates. Cells were treated with 0, 1, or 2 μM of pan-cathepsin inhibitor K777 
(AdipoGen Life sciences). At indicated time points, MTT was added, cells were lysed, and the absorbance 
was measured as described above. Fresh inhibitor was added to the cells every other day during the 
experiments. The experiment was started at day 4 post-lentiviral transduction and repeated three times. 
 
Lysosomal extracts 
Lysosomal extracts were prepared at day 6 post-lentiviral transduction by density gradient ultracentrifugation 
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using the Lysosome Enrichment Kit for Tissue and Cultured Cells (Thermo Scientific) according to the 
manufacturer’s protocol. One readout constituted of six independent spheroid culture samples pooled 
together. 
Presence of the lysosomes and purity of the collected fractions were verified using Western blot analysis 
with specific antibodies against lysosomes (LAMP2) and endoplasmic reticulum (Calnexin 1). Extracted 
lysosome pellets were stored at -80°C and further analysed by mass spectrometry. The experiment was 
performed two times. 
 
Mass spectrometric analysis of lysosomal lipids 
Total lipids in the lysosomal fractions were extracted using the Folch method (Folch et al., 1957). The lipids 
were identified and quantified by direct infusion electrospray ionization-tandem mass spectrometry as 
previously described (Tigistu-Sahle et al., 2017) with Agilent 6490 Triple Quad LC/MS with iFunnel 
technology (Agilent Technologies, Inc.). In brief, the lipid extracts in chloroform:methanol (1:2, v:v) were 
spiked with 10 internal standards and supplemented with 1 % NH4OH just prior infusion into the MS at a 
flow rate of 10 µl/min. The lipids were detected by using lipid-class specific detection modes (e.g. precursor 
ion m/z 264 for ceramide, m/z 184 for PC and neutral loss scan of 141 amu for PE) (Brugger et al., 1997). 
The spectra were processed by MassHunter Workstation qualitative analysis software (Agilent Technologies, 
Inc.) and the individual lipid species were quantified using the internal standards and free software called 
Lipid Mass Spectrum Analysis (Haimi et al., 2006). The results are described as mol % of each molecular 
species in its lipid class and marked as the number of acyl carbons:number of double bonds (e.g. 36:2).  
 
Clemastine treatment 
Clemastine fumarate salt (Sigma) cytotoxicity was tested at the indicated concentrations and time points 
using the MTT protocol as described above. LMP induction by clemastine was verified using the LGALS1 
puncta-staining assay described in the previous section (Aits et al., 2015). Cells were treated with DMSO or 
clemastine (1 µg/ml) at 37°C O/N and then lysed in RIPA-buffer for Western blot analyses. 
 
Animal experiments 
 26 
Animal experiments were approved by the Committee for Animal Experiments of the District of Southern 
Finland (ESAVI/6285/04.10.07/2014). Six-weeks-old immunocompromised NMRI-nu (Rj:NMRI-
Foxn1nu/Foxn1nu, Janvier Labs) mice were intracranially engrafted using a stereotaxic injector (World 
Precision Instruments) in the corpus callosum with 105 U87MG-GFP (n = 5) or U87MG-GFP-MDGI (n = 9) 
or LN229-GFP (n = 10) or  LN229-GFP-MDGI (n = 10) cells in 5 µl of PBS under ketamine and xylazine 
anesthesia. Post-operative painkiller (temgesic) was locally administered for two days. Following the same 
methodology, the clemastine preclinical study included the implantation of 105 cells dissociated from 
spheroids in 5 µl of PBS. The cohorts were distributed as BT12 parental (wt, Ve n = 9, Cle n = 12), shMDGI 
infected (Ve n = 5, Cle n = 5), control shRNA infected (Ve n = 5, Cle n = 5), ZH305 (Ve n = 10, Cle n = 
10), and BT13 (Ve n = 10, Cle n = 9).  Two weeks after tumour implantation, animals were randomized and 
clemastine (200 µl in PBS, intraperitoneally), was injected daily at the indicated doses for a duration of 12 
days in one cohort or until the physical manifestation of tumour burden for the survival studies. Control 
animals were treated under the same modalities with the vehicle (200 µl). At the endpoint of the experiment, 
animals were euthanised and brains were snap-frozen in -50°C isopentane (Honeywell) until tissue 
processing. 
 
Animal tissue processing and analysis 
Snap-frozen xenografted brains were cut using a cryotome (Cryostar NX70, Thermo Scientific) into series of 
9 µm-thick coronal sections collected from the frontal to the anteroposterior part of the tumour. Tissue 
sections were fixed in 4% PFA, blocked with 5% FBS and 0,03% Triton X (Sigma) and stained for the 
human vimentin or CD31 and MDGI by immunofluorescence. Whole brain sections were then scanned using 
a slide scanner (3DHistec). When required, verification of co-located staining was performed on 9 µm-
distant consecutive sections of each brain. Primary tumour volume determination was obtained by measuring 
the tumour area of 100 µm-distant consecutive sections covering the whole tumour (up to 30 histologic 
sections). Quantification of the different tumour parameters (tumour cell invasion, number of angiotropic 
satellites) was performed on 10 sections equally distributed along the whole tumour. 
 
Microscope imaging 
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The samples were imaged with a fluorescent upright microscope (Zeiss Axioplan and Axioimager) using 
AxioVision software. For the light microscopy, the cells were visualized and imaged with an inverted 
epifluorescence microscope (Zeiss Axiovert 200) equipped with AxioVision software. Confocal images were 
taken with Zeiss LSM 780 and 880 equipped with appropriate lasers. 
 
Patient study approval 
The ethics committee of the Hospital District of Helsinki and Uusimaa approved this study. The Ministry of 
Social Affairs and Health, Finland, permitted the use of tumour tissue. The ethics committee of the Pohjois-
Savo Health Care District municipalities permitted the use of human glioma tissue specimens (53/2009, 
1.8.2009-31.7.2019). 
 
Statistics 
Association of MDGI expression with other factors was tested using a Chi-squared test or Fisher’s exact test 
and Mann-Whitney’s U-test was used for the MDGI vs age analysis. All tests were 2-tailed. The cumulative 
survival rates of patients were estimated by using the Kaplan–Meier method, and survival between groups, 
hazard ratio (HR), and their 95 % confidence interval (95 % CI) were computed by using the Cox 
proportional hazards model. Overall survival was calculated from the date of the surgery of primary tumour 
to death, censoring patients still alive on the last date of follow-up. Glioma-specific survival was calculated 
from the date of the surgery of primary tumour to glioma caused death, censoring patients still alive or lost 
from follow-up for other cause on the last date of follow-up. Analyses were conducted with the IBM SPSS 
22 software. Results from all other experiments were analysed using the GraphPad Prism 7 software (La 
Jolla, USA) using two-tailed, nonparametric Mann-Whitney’s U-test. All the experiments were repeated at 
least three times with triplicates unless stated otherwise. For the lipidomics, two cell lines were used and the 
experiment was repeated two times. 
 
The paper explained 
 
Problem 
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Glia-derived brain tumours are the most frequent primary central nervous system cancers. In particular, its 
deadliest and the most frequent form, glioblastoma, is highly invasive cancer. Glioblastoma cells cannot be 
completely removed by surgery, and they exhibit high resistance to therapies. Finding a potential weakness 
of these invasive glioblastomas is required to improve the otherwise very poor patient prognosis. Current 
drugs suffer from poor specificity, which increases the off-target and side effects, and even poorer brain 
delivery due to the presence of a highly selective blood-brain-barrier (BBB). This study investigated a novel 
modality of the glioblastoma cell death, the lysosomal membrane permeabilization (LMP). It identifies the 
heart-type fatty acid binding protein (MDGI/FABP3) as a central regulator of the lysosomal membrane 
integrity in glioblastoma cells. The LMP can also be induced in vivo by administering drugs that can pass 
through the BBB, such as the cationic amphiphilic (CAD) antihistamine clemastine. 
 
Results 
Using patient databases, tissue samples, and live glioblastoma cells isolated from several patients, we show 
that MDGI is a biomarker of tumour invasiveness. Moreover, silencing of MDGI provoked death of 
glioblastoma cells through activation of the LMP. Using high-throughput lipidomics analyses, we were able 
to pinpoint the accumulation or depletion of very specific lysosomal phospholipids in the absence of MDGI. 
We linked the lysosomal membrane destabilisation induced by the silencing of MDGI to interrupted 
transportation of linoleic acid from the extracellular space to the intracellular compartment. Among the 
family of lysosomotropic LMP-inducing agents, the antihistamine clemastine was able to kill patient-derived 
glioblastoma cells without compromising the viability of non-cancer cells. Ultimately, the administration of 
clemastine to mice, bearing patient-derived tumours showed a very significant reduction of the invasive 
cancer cell density. Depending on the patient-isolated cells, clemastine-treatment left only a very 
circumscribed tumour or completely eradicated highly-diffusive glioblastoma. 
 
Impact 
Bearing in mind the chemoresistant nature of infiltrating gliomas, and the poor delivery of conventional 
 29 
drugs due to the BBB, the repurposing of antihistamines and other CADs to trigger the LMP in invasive 
neoplasms should be considered as an adjuvant therapy to the standard-of-care, i.e. the surgical resection of 
the primary tumour and conventional radio- and chemotherapies. 
 
For more information 
(i) http://gliovis.bioinfo.cnio.es 
(ii) The Ivy_GAP dataportal: http://glioblastoma.alleninstitute.org 
(iii) https://cellprofiler.org/ 
(iv) Laakkonen lab web-site: https://www.helsinki.fi/en/beta/tumor-progression-and-metastasis 
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Figure Legends 
 
Figure 1.  
Association of MDGI protein expression with patient survival and regulation of MDGI expression by 
hypoxia.  
A. Glioma tumour micro arrays (grade II-IV gliomas) were stained to visualise MDGI (red). Samples from 
the epileptic brain served as a negative control. Scale bar 100 µm. 
 
B. Overall survival of grade II and III glioma patients (n = 76) was significantly better when none/low 
MDGI (blue line) was detected compared to patients with moderate/high MDGI (red line) expression (P = 
0.007). The cumulative survival rates were estimated by using the Kaplan–Meier method.  
 
C. Analysis of the association of MDGI mRNA expression with glioma patient survival using the GlioVis 
data portal. In the TCGA GBMLGG dataset (n = 667), patients with low MDGI expression (green line; n = 
333, events = 101, median = 67,5) show significantly better survival than patients with high MDGI (red line; 
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n = 334, events = 138, median = 41.5) expression (P = 2e-04). HR = 0.62 (0.48 – 0.8). The cumulative 
survival rates were estimated by using the Kaplan–Meier method. 
 
D. In glioblastoma samples, highest MDGI expression was observed in the mesenchymal subtype (M) 
compared to the classical (Cl) or pro-neural (PN) ones. However, it did not reach the statistical significance. 
GlioVis data portal, TCGA GBM dataset, n = 156. Pairwise t-test with corrections for multiple testing, p-
values with Bonferroni correction.  
 
E. MDGI expression was high in the leading edge of the tumour (LE) and in infiltrating tumour cells (IT) in 
the IVY_Gap dataset (n = 122) where the gene expression profile in different anatomical structures of 
glioblastomas was analysed. LE, leading edge; IT, infiltrating tumour cells; CT, cellular tumour (cells within 
the tumour mass); PC, pseudopalisading cells; MP, microvascular proliferation. Numbers in the graph depict 
the P values: Pairwise t-test with corrections for multiple testing, p-values with Bonferroni correction.  
 
F. Western blot analysis shows MDGI expression in human glioma cells including patient-derived spheroids 
(S24, ZH161, ZH305, BT3, BT11, BT12, BT13), patient-derived adherent cells (BT5 and BT5R), and long-
term cell lines (U87MG, LN229, LN308). Numbers above the lanes show the relative expression of MDGI 
compared to the levels of -tubulin that served as loading control in each cell line. Representative Western 
blot image of 3 separate experiments is shown. 
 
G. High MDGI and HIF-1α expression in the patient-derived glioblastoma spheroids decreased significantly 
when cells were cultured in medium containing 10 % of serum (FBS) for seven days. Numbers show the 
relative expression of MDGI and HIF-1α compared to the levels of -tubulin. Expression in the serum-free 
medium was set as 1. Representative Western blot image of 2 separate experiments is shown. 
 
H. MDGI expression in adherent glioma cell lines and in glioma cell spheroids after 24h culture under 
hypoxia (1 % O2) or normoxia (21 % O2). Numbers show the relative MDGI expression compared to the 
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levels of -tubulin. Expression under normoxia was set as 1. Representative Western blot image of 3 
separate experiments is shown. 
 
Figure 2.  
MDGI expression promotes aggressive and invasive growth of glioma cells.  
A, B Representative whole coronal section micrographs of murine brain injected with GFP (A) or MDGI-
GFP (B) expressing U87MG glioma cells. Xenografted human cells were visualised by using anti-human 
vimentin (hVim) antibodies (red). Nuclei were visualised by using DAPI (white). Scale bar: 1 mm.  
 
C-F Micrographs of consecutive (separating distance: 9 µm) brain sections stained for human glioma cells 
using antibodies specific for human vimentin (hVim red in C and D), MDGI (green in E and F), and CD31 
(red in E and F). Dashed lines separate the primary tumour mass and the normal brain. Nuclei were 
visualised by using DAPI (blue). Arrows in D point to the angiotropic tumours. Arrows in F point to the 
MDGI-expressing angiotropic tumour cells.  Scale bar: 50 µm.  
 
G. Quantification of the number of U87MG secondary tumours (diameter >300 µm) detected in the whole 
brain (GFP: n = 5, MDGI-GFP: n = 9). Data are represented as mean ± SEM. **P < 0.01, two-tailed, 
nonparametric Mann-Whitney’s U-test.  
 
H. Quantification of the number of invasive U87MG cells that grew next to brain blood vessels (angiotropic 
co-opting tumour cells, diameter <300 µm) (GFP: n = 5, MDGI-GFP: n = 9). Data are represented as mean ± 
SEM. ****P < 0.0001, two-tailed, nonparametric Mann-Whitney’s U-test. 
 
I, J Representative micrographs of whole murine brain coronal sections injected with GFP (I) or GFP-MDGI 
(J) expressing LN229 glioma cells. Xenografted human cells were visualised by using anti-human vimentin 
(hVim) antibodies (red). Nuclei were visualised by using DAPI (white). Scale bar: 1 mm.  
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K-N Micrographs of consecutive (separating distance: 9 µm) brain sections stained for human glioma cells 
using antibodies specific for human vimentin (hVim red in K and L), MDGI (green in M and N), and CD31 
(red in M and N). Dashed lines separate the primary tumour mass and the normal brain. Nuclei were 
visualised by using DAPI (blue). ). Arrows in L point to the angiotropic tumours. Arrows in N point to the 
MDGI-expressing angiotropic tumour cells.  Scale bar: 50 µm.  
 
O. Quantification of the number of invasive LN229 cells detected in the brain (GFP: n = 10, MDGI-GFP: n 
= 10). Data are represented as mean ± SEM. ****P < 0.0001, two-tailed, nonparametric Mann-Whitney’s U-
test.  
 
P. Quantification of the number of invasive LN229 cells that grew next to brain blood vessels (angiotropic 
co-opting tumour cells, diameter <300 µm) detected in the brain (GFP: n = 10, MDGI-GFP: n = 10). Data 
are represented as mean ± SEM. Data are represented as mean ± SEM. ****P < 0.0001, two-tailed, 
nonparametric Mann-Whitney’s U-test.  
 
Figure 3.  
MDGI silencing reduces glioma cell growth and viability both in vitro and in in vivo.  
A. Transmitted light micrographs of MDGI-silenced (shMDGI1 and shMDGI2) and control (Scr) patient-
derived BT12 and BT13 spheroids 11 days after gene silencing. Representative images of at least 3 
independent experiments are shown. Scale bar: 200 μm.  
 
B. Methylcellulose assay demonstrating the ability for self-renewal of control (Scr) and MDGI-silenced 
(shMDGI1 and shMDGI2) patient-derived BT12 and BT13 cells after three weeks of culture. Representative 
images of at least 3 independent experiments are shown. Scale bar: 200 μm. 
 
C. Quantification of the colony size in methylcellulose of MDGI-silenced (sh1 and sh2) cells relative to the 
controls (Scr) that is set as 100 (n = 3). Data are represented as mean ± SD. ***P < 0.001, two-tailed, 
 40 
nonparametric Mann-Whitney’s U-test.  
 
D. MTT-proliferation assay of control (Scr) and MDGI-silenced (shMDGI1) BT12 and BT13 cells. The 
values of each cell line were normalized to the values at day 1 marked with a dashed line (n = 3). Data are 
represented as mean ± SD. ***P < 0.001, two-tailed, nonparametric Mann-Whitney’s U-test. 
 
E, F Representative whole coronal section micrographs of murine brain injected intracranially with control 
(BT12 Scr, n = 5) and MDGI-silenced (BT12 sh1, n = 5) BT12 cells. After four weeks animals were 
sacrificed, the brains were excised and prepared for immunohistochemistry. Control (Scr) cells grew very 
similarly to the parental BT12 cells forming a tumour mass with invasive tumour cells (single cell invasion) 
that eventually co-opted existing blood vessels (angiotropism) and formed secondary tumours (upper 
panels). No tumour growth was observed when MDGI-silenced cells were implanted (lower panels). Glioma 
cells were visualised by using anti-human vimentin (hVim red) and blood vessels using anti-podocalyxin 
antibodies (green). Nuclei were visualised by using DAPI (white). Scale bar: 1 mm (E) and 50 µm (F). 
 
Figure 4.  
MDGI silencing induces cell death via lysosomal membrane permeabilization (LMP).  
A. Binding of Annexin V Alexa Fluor 488 to control (Scr) and MDGI-silenced (shMDGI1) BT12 cells was 
measured by flow cytometric analyses five days after silencing. The analysis was performed by gating the 
cells into two populations: P1 (small, granular) and P2 (normal-sized cells) (30 000 analysed events/cell line, 
n = 3).  
 
B. Geometric mean fluorescence (FL-1) relative to the controls (Scr) that was set as 1 in P1 and P2 in 
MDGI-silenced (shMDGI1) cells. Data are represented as mean ± SD. *P < 0.05, two-tailed, nonparametric 
Mann-Whitney’s U-test. 
 
C, D Representative micrographs of non-treated control BT12 cells (C) and cells treated with 2 mM LLOMe 
for 4 h (D) before staining with the anti-galectin-1 antibodies (LGALS1) (green). Nuclei were visualised by 
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using DAPI (blue). Scale bar: 10 µm. 
 
E, F Representative micrographs of LGALS1-stained (green) BT12 control (E) and MDGI-silenced cells (F) 
six days after silencing. Nuclei were visualised by using DAPI (blue). Scale bar: 10 µm. 
 
G, H Representative micrographs of LGALS1-stained (green) BT13 control (G) and MDGI-silenced cells 
(H) six days after silencing. Nuclei were visualised by using DAPI (blue). Scale bar: 10 µm. 
 
I. Percentage of LGALS1-positive puncta staining in the control (Scr) and MDGI-silenced (sh1) cells. In 
total 0.4-1.2x104 LGALS1-stained cells were analysed from 50 mm2 coverslip areas (n = 6). Data are 
represented as mean ± SD. **P < 0.01, two-tailed, nonparametric Mann-Whitney’s U-test. 
 
J. Quantification of the percentage of dead cells six days after MDGI silencing and LGALS1 staining (n = 
100) in control (Scr) and MDGI-silenced (sh1) BT12 and BT13 cells. Data are represented as mean ± SD. 
**P < 0.01, two-tailed, nonparametric Mann-Whitney’s U-test. 
 
K. Cytoplasmic cathepsin B activity in the control (Scr) and MDGI-silenced (sh1) BT12 and BT13 cells. 
Data are represented as mean ± SD. **P < 0.01; **P < 0.001, two-tailed, nonparametric Mann-Whitney’s U-
test. 
 
L. Number of live cells in MDGI-silenced BT12 and BT13 cells incubated without (sh1) or with (sh1+K777) 
the pan-cathepsin inhibitor (K777) after 1, 3 and 5 days of incubation. Data shows the percentage of live 
cells compared to the control (Scr) cells set as 100 %. Data are represented as mean ± SD. *P < 0.05; **P < 
0.01, two-tailed, nonparametric Mann-Whitney’s U-test. 
 
Figure 5.  
MDGI silencing induces changes in lysosomal membrane lipid composition. 
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A. Proportions (mol %) of saturated (Sat), monounsaturated (Mono), diunsaturated (Di; total of 2 double 
bonds in the acyl chains), and polyunsaturated (Poly; total of 3-7 double bonds in the acyl chains) lipid 
species from the two main phospholipid classes (phosphatidylcholine PC and phosphatidylethanolamine PE) 
of the lysosomal fractions of the BT12 and BT13 control (Scr) and MDGI-silenced (shMDGI) cells. A 
representative graph of two independent experiments is shown. 
 
B. Fold change of the main PC and PE species in the lysosomal membranes of MDGI-silenced (shMDGI) 
and control (Scr) cells (Log2, by mol % data). Abbreviations: [Lipid class] [total number of acyl chain 
carbons]:[total number of double bonds in the chains]. A representative heatmap of two independent 
experiments is shown. 
 
C. Profiles of ceramide (Cer) species (mol %) in the lysosomal membranes of MDGI-silenced (shMDGI) 
and control (Scr) BT12 and BT13 cells. Abbreviations: Cer [number of acyl chain carbons]:[number of 
double bonds in the acyl chain]; all principal species containing a sphingosine chain. A representative graph 
of two independent experiments is shown. 
 
D. Ratio of the 24:1 to 24:0 (mol %.mol %) Cer species in the lysosomal membranes of MDGI-silenced 
(shMDGI) and control (Scr) BT12 and BT13 cells. A representative graph of two independent experiments is 
shown. 
 
Figure 6.  
Antihistamine treatment induces glioma cell death via lysosomal membrane permeabilization (LMP). 
A. Measurement of the BT12, BT13, and ZH305 glioblastoma cell viability using the MTT-assay at the 
indicated clemastine concentrations and time points (n = 12). A dashed line marks the 50 % cell viability. 
 
B. Measurement of the viability of normal human endothelial cells (HuAR2T), normal human astrocytes 
(NHA), and embryonic kidney (HEK293T) cells at the indicated clemastine concentrations and time points 
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(n = 12). A dashed line marks the 50 % cell viability.  
 
C. Representative micrographs of BT12, BT13, and ZH305 glioblastoma cells treated with 1 µg/ml of 
clemastine for 24 h and stained with anti-galectin-1 (LGALS1) antibody (green). Non-treated cells served as 
control. Nuclei were visualised by using DAPI (blue). Scale bar: 20 µm.  
 
D. Representative micrographs of normal human endothelial cells (HuAR2T), normal human astrocytes 
(NHA), and kidney cells (HEK293T) treated with 1 µg/ml clemastine for 24 h and stained with anti-
LGALS1 antibody (green). Non-treated cells served as control. Nuclei were visualised by using DAPI (blue). 
Scale bar: 10 µm.  
 
Figure 7.  
Clemastine treatment eradicates invasive glioma cells.  
A. Representative whole coronal section micrographs of murine brain intracranially implanted with various 
glioblastoma cells), and daily treated with saline vehicle (Ve) or 50 mg/kg clemastine (Cle, 100 mg/kg single 
dose administered at day 1) for 12 days starting at day 15 after tumour implantation. BT12 (parental (wt, Ve 
n = 9, Cle n = 12) and control shRNA infected (Ve n = 5, Cle n = 5), ZH305 (Ve n = 10, Cle n = 10), and 
BT13 (Ve n = 10, Cle n = 9). Human glioma cells were visualised with an anti-human vimentin (hVim, red). 
Nuclei were visualised by using DAPI (white). Scale bar: 1 mm.  
 
B, C Quantification of the number of the invading single BT12 wt glioblastoma cells (B) and distance of the 
invaded cells from the primary tumour (C) of vehicle (black bars, Ve) and clemastine-treated (white bars, 
Cle) animals (Ve n = 9, Cle n = 12). Data are represented as mean ± SEM. ****P < 0.0001, two-tailed, 
nonparametric Mann-Whitney’s U-test. 
 
D. Quantification of the number of secondary tumours (diameter >300 µm) in the murine brain for the 
indicated treatments and tumour models. BT12 (parental (wt, Ve n = 9, Cle n = 12) and control shRNA 
infected (Ve n = 5, Cle n = 5), and BT13 (Ve n = 10, Cle n = 9). Data are represented as mean ± SEM. 
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****P < 0.0001, two-tailed, nonparametric Mann-Whitney’s U-test. 
 
E. Quantification of the number of angiotropic BT12 cells that have co-opted existing blood vessels in the 
murine brain for the indicated treatments (Ve n = 9, Cle n = 12). Data are represented as mean ± SEM. 
****P < 0.0001, two-tailed, nonparametric Mann-Whitney’s U-test. 
 
F, G. Quantification of the number of TUNEL positive cells in the murine brain for the indicated treatments 
(Ve n = 9, Cle n = 12). Data are represented as mean ± SEM. ****P < 0.0001, two-tailed, nonparametric 
Mann-Whitney’s U-test. 
 
G. Representative micrographs of consecutive brain sections (separating distance: 9 µm) showing xenografts 
treated with vehicle or clemastine and labelled with the anti-human vimentin (red in left panels) and TUNEL 
(red in right panels). Nuclei were visualised by using DAPI (white). Scale bar: 50 µm.  
 
H. Kaplan-Meier survival curve of the BT12 xenografted animals treated with vehicle (green line, n = 15) 
and clemastine (black line, n = 12). Survival of the animals has been measured and pooled from two 
independent experiments. P = 0.044, Mantel-Cox Log-rank test. 
 
Table 1. Cox multivariant analysis of association of MDGI expression and tumour grade on glioma patient 
survival. 
Covariate  (SE) HR P 
MDGI expression 
Positive vs. negative 
 
0.56 (0.264) 
 
1.76 (1.05 to 2.94) 
 
0.033 
Tumour grade 
III vs. II 
0.76 (0.264 2.14 (1.28 to 3.60) 0.004 
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